trpa1-chemotherapy-induced-peripheral-neuropathy-promising-target-for

TRPA1 in Chemotherapy-Induced Peripheral Neuropathy: A Promising Target for Immunomodulation and Anti-Inflammatory Therapy

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and serious clinical condition that results when a chemotherapeutic agent damages the ...

Liaoning University of Traditional Chinese Medicine

The incidence and mortality rates of digestive tract tumors, especially gastric and colorectal cancers, are high worldwide. Owing to their unique advantages, such as efficient drug loading, safety, and targeting properties, nanoparticles (NPs) have demonstrated great potential in the treatment of gastrointestinal tumors. However, their practical application is limited by several factors, such as high costs, few clinical trials, and long approval periods. In this review, we summarize three types of immunotherapeutic nanomaterial drugs for gastrointestinal tumors: organic, inorganic, and hybrid nanomaterials. This article also discusses the current status of research and development in this field and the advantages of each type of material to provide theoretical references for developing new drugs and advancing clinical research.

Nanomaterials for targeted drug delivery for immunotherapy of digestive tract tumors.

Oxaliplatin, a third-generation platinum-based chemotherapeutic agent, has shown substantial efficacy in cancer treatment. However, its associated side effects, particularly chemotherapy-induced peripheral neuropathic pain (CIPNP), continue to challenge cancer survivors globally. Clinically, it frequently presents as numbness, coldness, and discomfort in the limbs and extremities. Duloxetine is advised for analgesic purposes. Despite its clinical relevance, both the application methods and the underlying mechanisms of oxaliplatin-induced CINP warrant further investigation. Consequently, more precise animal models are needed to explore the mechanisms and progression of this condition. This review consolidates recent advancements in rat and mouse models of oxaliplatin-induced CINP, with the aim of enhancing modeling success rates and developing models that more accurately mirror disease progression. Such models are essential for advancing clinical research and drug development.

Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress.

The complexity of the tumor immune microenvironment (TIME), which is composed of mainly tumor cells, immune cells, and cytokines, is a major obstacle limiting the effectiveness of immunotherapy, and the interactions among these factors in the TIME determine the efficacy of antitumor immunity. Over the past few years, nanomaterials, owing to their unique physicochemical properties, multifunctionality, and good targeting ability, have gradually become important tools for modulating the immune microenvironment. By precisely delivering immunomodulatory factors, nanomaterials can effectively activate dendritic cells (DCs), enhance the function of effector T cells, and reverse the immunosuppressive state of tumor-associated macrophages (TAMs). In addition, nanomaterials can alleviate the local hypoxic and acidic tumor microenvironment, which in turn promotes immune cell function and enhances the antitumor immune effect. In light of the aforementioned associations, we summarize the existing studies, systematically describe the latest research progress on the use of nanomaterials in regulating the tumor immune microenvironment, and analyze the potential applications and challenges in tumor immunotherapy, with the goal of providing new therapeutic directions and strategies for tumor immunotherapy.

Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy.

The intestinal microbiota, present in vast numbers within the human body, plays a pivotal role, with its composition and abundance varying significantly across individuals. This gut microbiota not only contributes to normal physiological development but also impacts the initiation, progression, resolution, and prognosis of various diseases. Recent studies have increasingly illuminated the connection between intestinal microbiota and pain, with a particular focus on the relationship between gut microbiota and neuropathic pain (NP). NP, an acute and chronic pain disorder arising from sensory nervous system injury, encompasses both peripheral and central neuropathic pain. Evidence suggests that intestinal microbiota influences NP occurrence and may modulate its severity. This review synthesizes current research findings on the microbiota-NP relationship, aiming to establish a theoretical foundation for future clinical investigations.

Advances in the Study of Intestinal Microbiota and Neuropathic Pain.

Peripheral Nerve Injury (PNI) is a common condition in modern clinical practice, characterized by a high incidence and significant debilitating consequences. This narrative review systematically delineates the dual functions of key pro-inflammatory (e.g., IL-1β, IL-6, IL-17) and anti-inflammatory (e.g., IL-4, IL-10, IL-13) interleukins in the spatiotemporal context of nerve injury. This is a narrative review, the review systematically summarizes the dual pro-inflammatory and anti-inflammatory roles of interleukins in peripheral nerve injury. The therapeutic potential of interleukin-based treatment strategies, including inhibitors, agonists, and their combined applications with cell therapy, gene therapy, physical therapy, etc., was explored, and the limitations of current research and future research directions were pointed out. By synthesizing current evidence, this review aims to provide a comprehensive mechanistic overview and highlight emerging interleukin-centric therapeutic paradigms for PNI.

The role of interleukins in peripheral nerve injury and the current status of treatment.

Despite the clinical application of Ophiopogon japonicus in idiopathic pulmonary fibrosis (PF), its key anti-fibrotic components and underlying mechanisms remain poorly defined. Using a bleomycin-induced murine PF model, we systematically compared the efficacy of the total extract (OJTE), polysaccharides (OJTP), saponins (OJTS), and flavonoids (OJTF). The active component was further investigated via integrated metagenomics and metabolomics (serum/feces) to decipher the gut-lung axis mechanism. All O. japonicus components attenuated lung injury and collagen deposition, with OJTP demonstrating the most potent efficacy (reducing lung hydroxyproline content by 42.12% (p < 0.01) compared to the model group). Multi-omics analysis revealed that OJTP remodeled the gut microbiota, notably enriching probiotic strains such as Muribaculaceae bacterium (logFC = 2.17) and Duncaniella muricolitica (logFC = 2.06), as well as the polysaccharide-utilizing species Prevotella sp. MGM2 (logFC = 2.79). Concomitantly, OJTP significantly altered host metabolism, upregulating key metabolites including urobilinogen (p < 0.0001) and 5-amino valeric acid betaine (5-AVAB, p < 0.002). These metabolites are implicated in porphyrin and amino acid metabolism, respectively. Correlation networks further established strong associations between these OJTP-modulated microbes and metabolites. Our study first identifies OJTP as the primary bioactive component of O. japonicus against PF. We propose a novel trans-organ mechanism wherein OJTP ameliorates PF via orchestrating a "gut microbiota-metabolite" axis, highlighting the therapeutic potential of targeting polysaccharide-probiotic synergy.

Article	Year
Nanomaterials for targeted drug delivery for immunotherapy of digestive tract tumors. Frontiers in immunology\| PubMed ID: 40109337	2025
Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress. Frontiers in pharmacology\| PubMed ID: 40520182	2025
Modulation of the immune microenvironment using nanomaterials: a new strategy for tumor immunotherapy. Frontiers in immunology\| PubMed ID: 40672947	2025
Advances in the Study of Intestinal Microbiota and Neuropathic Pain. Frontiers in bioscience (Landmark edition)\| PubMed ID: 41351422	2025
The role of interleukins in peripheral nerve injury and the current status of treatment. Frontiers in immunology\| PubMed ID: 41573554	2025
Ophiopogon japonicus polysaccharide ameliorates pulmonary fibrosis via gut microbiota-metabolite crosstalk. Microbial pathogenesis\| PubMed ID: 41912071	2026

Yue Shen

Biography

JoVE Journal Publications

Other Publications